Company intelligence / Profile preview

Filkri

Ownership: Private
Development stage: Other

Overview

Filkri is an early-stage biotechnology company focused on developing next-generation inhibitors for KRAS-driven cancers. The company is specifically working on novel small molecule approaches to target KRAS mutations that have remained elusive to first-generation inhibitors. By leveraging advanced medicinal chemistry, Filkri aims to expand the therapeutic window and overcome resistance mechanisms commonly seen in KRAS-mutant solid tumors. Their current research is centered on optimizing lead candidates for non-small cell lung cancer and gastrointestinal malignancies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Filkri.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Filkri.

Explore the full profile